==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Research Articles from literature

  1. A comparison of lepirudin and argatroban outcomes.
  2. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.
  3. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.
  4. Effects of additives on heat denaturation of rhDNase in solutions.
  5. The role of dornase alfa in the treatment of cystic fibrosis.
  6. Dornase alfa for cystic fibrosis.
  7. Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases.
  8. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
  9. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
  10. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.
  11. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin
  12. Heparin-induced thrombocytopenia: treatment options and special considerations.
  13. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
  14. The use of bivalirudin in patients with renal impairment.
  15. A 24-hour continuous infusion study of bivalirudin in the rat.
  16. Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series.
  17. Pharmacological strategies for the prevention of Alzheimer's disease.
  18. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity.
  19. Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietin.
  20. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
  21. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening.
  22. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
  23. Thermal denaturation of human gamma-interferon. A calorimetric and spectroscopic study.
  24. Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia.
  25. Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique.
  26. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII.
  27. TTD: Therapeutic Target Database.
  28. Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
  29. Macromolecular structural elucidation with solid-state NMR-derived orientational constraints.
  30. Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles.
  31. Gramicidin D conformation, dynamics and membrane ion transport.
  32. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.
  33. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
  34. Basic principles of intravenous immunoglobulin (IVIg) treatment.
  35. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
  36. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
  37. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.
  38. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.
  39. The platelet-related effects of tenecteplase versus alteplase versus reteplase.
  40. Tenecteplase for the treatment of massive and submassive pulmonary embolism.
  41. Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI.
  42. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
  43. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
  44. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.
  45. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.
  46. The platelet-related effects of tenecteplase versus alteplase versus reteplase.
  47. Tenecteplase for the treatment of massive and submassive pulmonary embolism.
  48. Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI.
  49. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.
  50. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.
  51. Domain structure and domain-domain interactions of recombinant tissue plasminogen activator.
  52. Distribution and characteristics of Poliovirus strains circulating in Poland in 1968-1972. Genetic variation of strains isolated in various secretion periods and clones isolated from vaccines
  53. The effects of some polypeptides on the systemic blood pressure of sheep.
  54. Alkaline phosphatase of Blastocladiella emersonii: partial purification and characterization.
  55. The role of IFN-gamma in immune responses to viral infections of the central nervous system.
  56. Interferon-gamma: an overview of signals, mechanisms and functions.
  57. Modulation of HIV-1 transcription by cytokines and chemokines.
  58. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis.
  59. Nef: "necessary and enforcing factor" in HIV infection.
  60. The roles of IFN gamma in protection against tumor development and cancer immunoediting.
  61. Three-dimensional structure of recombinant human interferon-gamma. Science.
  62. Structure of the human immune interferon gene.
  63. Thermal effects on an enzymatically latent conformation of coagulation factor VIIa.
  64. Factors regulating amino acid release from extrasplanchnic tissues in the rat.
  65. Recombinant activated factor VII for acute intracerebral hemorrhage.
  66. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
  67. Treatment of traumatic bleeding with recombinant factor VIIa.
  68. The use of recombinant factor VIIa in the treatment of bleeding disorders.
  69. A review of potential cardiovascular uses of intravenous glucagon administration.
  70. Botulinal neurotoxins: revival of an old killer.
  71. Hyperhidrosis: evolving therapies for a well-established phenomenon.
  72. Clostridium botulinum: a bug with beauty and weapon.
  73. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
  74. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
  75. Thermal stability of human chorionic gonadotropin. Reversible dissociation of subunits at neutral pH.
  76. Lutropin alfa.
  77. Recombinant follitropin alfa/lutropin alfa in fertility treatment.
  78. Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick.
  79. Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats.
  80. Gastrointestinal absorption.
  81. Novel insulin analogues and its mitogenic potential.
  82. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.
  83. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
  84. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
  85. An overview of insulin glargine.
  86. Insulin glargine (Aventis Pharma).
  87. Insulin glargine: a systematic review of a long-acting insulin analogue.
  88. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
  89. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
  90. Multiple forms of cyclohexanone oxygenase from Nocardia globerula CL1.
  91. Fluroescence of proteins in 6-M guanidine hydrochloride. A method for the quantitative determination of tryptophan.
  92. A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults.
  93. Polymorphism of microcrystalline urate oxidase from Aspergillus flavus.
  94. Gaucher Disease
  95. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
  96. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
  97. Probing the equilibrium denaturation of the serpin alpha(1)-antitrypsin with single tryptophan mutants; evidence for structure in the urea unfolded state.
  98. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids.
  99. Pegaspargase: a review of clinical studies.
  100. Serum albumin: search for new sites with esterase activity according to molecular modeling data.
  101. Role of human albumin in the management of complications of liver cirrhosis.
  102. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
  103. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
  104. Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes.
  105. Infliximab for the treatment of fistulas in patients with Crohn's disease
  106. Infliximab maintenance therapy for fistulizing Crohn's disease
  107. Crohn's disease: step up or top down therapy
  108. Follitropin alpha in infertility: a review.
  109. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules
  110. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice
  111. Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression
  112. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology
  113. Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task.
  114. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
  115. http://www.google.com/patents/EP0422697A1?cl=en
  116. Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31
  117. Ongoing adjuvant trials with trastuzumab in breast cancer.
  118. Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab.
  119. Molecular targets for breast cancer therapy and prevention.
  120. Biologic and therapeutic role of HER2 in cancer.
  121. Development of Herceptin resistance in breast cancer cells.
  122. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
  123. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
  124. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
  125. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura
  126. The epitope recognized by rituximab
  127. Interstitial pneumonitis related to rituximab therapy
  128. http://www.google.com/patents/EP2231183A2?cl=en#
  129. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers
  130. Development of daptomycin for gram-positive infections.
  131. The dearth of new antibiotic development: why we should be worried and what we can do about it.
  132. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
  133. Update on daptomycin: the first approved lipopeptide antibiotic.
  134. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
  135. Clostridium botulinum: a bug with beauty and weapon
  136. Botulinum toxin injections for paediatric incontinence
  137. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.
  138. Reshaping human antibodies for therapy.
  139. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
  140. ttp://www.google.com/patents/WO2013006706A1?cl=en.
  141. http://www.lens.org/lens/patent/US_4671958_A
  142. http://www.google.ca/patents/US4741900
  143. http://www.google.com/patents/US5162504
  144. Drugs and their molecular targets: an updated overview.
  145. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
  146. Follitropin alpha in infertility: a review.
  147. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
  148. Efalizumab.
  149. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid.
  150. Unfolding of acrylodan-labeled human serum albumin probed by steady-state and time-resolved fluorescence methods.
  151. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results.
  152. A comparison of the hemolytic potential of Optison and Albunex in whole human blood in vitro: acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations.
  153. Albunex Does Not Increase the Sensitivity of the Lung to Pulsed Ultrasound.
  154. Clinical usefulness of intravenous albunex for the Doppler assessment of aortic stenosis.
  155. Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure.
  156. Thermal stability of human chorionic gonadotropin. Reversible dissociation of subunits at neutral pH.
  157. Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system.
  158. Sickness in pregnancy and sex of child.
  159. Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa (Ovidrel) in the late follicular phase.
  160. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
  161. Reduced-dose cyclophosphamide in combination with fludarabine and anti-thymocyte globulin as a conditioning regimen for allogeneic hematopoietic stem cell transplantation for aplastic anemia.
  162. A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
  163. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies.
  164. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study.
  165. Rabbit antithymocyte globulin as first-line therapy for severe aplastic anemia.
  166. Early intensified intravenous cyclosporine therapy predicts favorable response to immunosuppressive therapy with rabbit antithymocyte globulin in patients with severe aplastic anemia.
  167. Steroid-Free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients
  168. Transient grades 3 to 4 acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation.
  169. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers
  170. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers
  171. FDA advisers recommend approval of biosimilar filgrastim.
  172. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
  173. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis
  174. comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
  175. Christmas disease: a condition previously mistaken for haemophilia.
  176. Isolation and characterization of a cDNA coding for human factor IX.
  177. Living donor liver transplantation from an asymptomatic donor with mild coagulation factor IX deficiency: report of a case.
  178. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.
  179. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
  180. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
  181. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000212/WC500050140.pdf
  182. Long-term successful healing of ulcerated necrobiosis lipoidica after topical therapy with becaplermin.
  183. A matched cohort study of the risk of cancer in users of becaplermin.
  184. Becaplermin: infections.
  185. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
  186. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
  187. Off-label use of becaplermin gel (recombinant platelet-derived growth factor-BB) for treatment of mucosal defects after corticocancellous bone graft: report of 2 cases with review of the literature.
  188. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
  189. The Impact of Oxygen Tension on Cell Density and Metabolic Diversity of Microbial Communities in Alkane Degrading Continuous-Flow Cultures.
  190. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
  191. Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.
  192. Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme) to agalsidase alfa (replagal).
  193. Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.
  194. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
  195. First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects.
  196. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
  197. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
  198. Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
  199. Recombinant interferon alfa-2b in the treatment of vision-threatening capillary hemangiomas in childhood.
  200. The response of the hepatitis C and hepatitis G viruses to treatment with recombinant interferon alfa-2b.
  201. Developmental changes in hypothalamic oxytocin and oxytocin receptor mRNA expression and their sensitivity to fasting in male and female rats.
  202. Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia.
  203. Oxytocin receptor gene and racial ingroup bias in empathy-related brain activity.
  204. Oxytocin, testosterone, and human social cognition.
  205. Self-soothing behaviors with particular reference to oxytocin release induced by non-noxious sensory stimulation.
  206. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis.
  207. Resistance to enfuvirtide, the first HIV fusion inhibitor.
  208. Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity.
  209. Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico.
  210. Gene fragment polymerization for increased yield of recombinant HIV fusion inhibitor enfuvirtide.
  211. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
  212. Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
  213. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
  214. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.
  215. In vitro characterization of a sustained-release formulation for enfuvirtide.
  216. AAP Issues Updated Guidance on Palivizumab Prophylaxis for RSV Infection.
  217. Use of palivizumab is underestimated in the Swedish Prescribed Drug Register - implications for register-based drug studies.
  218. Palivizumab: four seasons in Russia.
  219. Medication highlights: new recommendations for palivizumab (Synagis).
  220. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.
  221. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
  222. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
  223. Similar survival in patients following heart transplantation receiving induction therapy using daclizumab vs. basiliximab.
  224. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
  225. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
  226. A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.
  227. Daclizumab: Clinical trial of monoclonal antibody for the treatment of MS.
  228. Alopecia areata universalis complicating daclizumab therapy for uveitis.
  229. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey.
  230. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
  231. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
  232. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion.
  233. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
  234. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
  235. Lung cancer and concurrent or sequential lymphoma: Two case reports with hypersensitivity to bevacizumab and a review of the literature.
  236. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results.
  237. 99mTc-Arcitumomab
  238. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels.
  239. Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration.
  240. Detection of distant medullary thyroid carcinoma metastases by Tc-99m arcitumomab scintigraphy.
  241. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
  242. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.
  243. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
  244. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
  245. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
  246. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
  247. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
  248. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
  249. Panitumumab: a review of its use in metastatic colorectal cancer.
  250. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
  251. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.,
  252. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
  253. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
  254. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
  255. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
  256. Idursulfase in Hunter syndrome treatment.
  257. Idursulfase for the treatment of mucopolysaccharidosis II.
  258. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.
  259. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
  260. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
  261. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
  262. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
  263. Late-onset Glycogen Storage Disease type 2.
  264. Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness.
  265. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation.
  266. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
  267. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
  268. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.
  269. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
  270. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
  271. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results.
  272. Mecasermin (recombinant human insulin-like growth factor I).
  273. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
  274. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?.
  275. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
  276. Therapies for diabetes: pramlintide and exenatide.
  277. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
  278. Pramlintide in the treatment of diabetes mellitus.
  279. Pramlintide for the treatment of diabetes mellitus.
  280. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
  281. Galsulfase (Naglazyme) therapy in infants with mucopolysaccharidosis VI.
  282. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
  283. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
  284. Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme].
  285. CTLA4Ig: a novel inhibitor of costimulation.
  286. Abatacept.
  287. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
  288. T-cell-targeted therapies in rheumatoid arthritis.
  289. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
  290. Abatacept for rheumatoid arthritis: a Cochrane systematic review.
  291. Abatacept for rheumatoid arthritis.
  292. Role of abatacept in the management of rheumatoid arthritis.
  293. Abatacept.
  294. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
  295. Insulin aspart: promising early results borne out in clinical practice.
  296. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
  297. Pharmacology of insulin detemir.
  298. Defining the role of insulin detemir in Basal insulin therapy.
  299. Actions of insulin beyond glycemic control: a perspective on insulin detemir.
  300. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
  301. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
  302. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
  303. Insulin glulisine complementing basal insulins: a review of structure and activity.
  304. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.
  305. Insulin glulisine.
  306. Insulin glulisine: a review of its use in the management of diabetes mellitus.
  307. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
  308. Insuline glusine (Apidra): a new rapid-acting insulin.
  309. Insulin glulisine.
  310. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
  311. Pegaptanib in the treatment of wet, age-related macular degeneration
  312. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
  313. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
  314. Safety and efficacy of nesiritide in pediatric heart failure.
  315. Nesiritide: a new therapy for the treatment of heart failure.
  316. Nesiritide: a novel approach for acute heart failure.
  317. Nesiritide: review of clinical pharmacology and role in heart failure management.
  318. Brain natriuretic peptide (nesiritide) in the treatment of heart failure.
  319. Thymalfasin for the treatment of chronic hepatitis B.
  320. Thymalfasin: an immune system enhancer for the treatment of liver disease.
  321. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
  322. Thymalfasin: an immune system enhancer for the treatment of liver disease.
  323. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
  324. Comparison of assays for determination of peptide content for lyophilized thymalfasin.
  325. Thymalfasin for the treatment of chronic hepatitis C infection.
  326. Thymalfasin for the treatment of chronic hepatitis C infection.
  327. Thymalfasin: clinical pharmacology and antiviral applications.
  328. Thymosin alpha1: the regulator of regulators.
  329. Pharmacokinetics of defibrotide in healthy volunteers.
  330. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.
  331. Pharmacokinetics, absorption, distribution and disposition of [125I]-defibrotide following intravenous or oral administration in the rat.
  332. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.
  333. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.
  334. An integrated view of the activities of defibrotide.
  335. Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells.
  336. Medical Product Agency about Multiferon: positive benefit-risk relation.
  337. The discussion about Multiferon should go on.
  338. Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches.
  339. Successful long-term application of highly purified natural interferon-alpha (multiferon) after preceding interferon approaches in a chronic hepatitis C patient with thrombocytopenia.
  340. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.
  341. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
  342. Glatiramer acetate (Copaxone).
  343. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma.
  344. Parathyroid hormone in the treatment of osteoporosis.
  345. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.
  346. Teicoplanin metabolism in humans.
  347. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations.
  348. Teicoplanin: an investigational glycopeptide antibiotic.
  349. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
  350. Use of canakinumab in the cryopyrin-associated periodic syndrome.
  351. Tumor immunotherapy directed at PD-1.
  352. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
  353. Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
  354. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
  355. Ipilimumab-Associated Bilateral Optic Neuropathy.
  356. Ipilimumab-induced toxicities and the gastroenterologist.
  357. Medical and surgical treatmets for tinnitus: the efficacy of combined treatment with sulodexide and melatonin.
  358. Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS).
  359. Role of sulodexide in the treatment of CVD.
  360. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects.
  361. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease.
  362. Pharmacological profile of sulodexide.
  363. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
  364. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide.
  365. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
  366. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient.
  367. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
  368. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever.
  369. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
  370. Developments in the pharmacotherapeutic management of osteoporosis.
  371. Effective treatment of delayed union of a lumbar vertebral fracture with daily administration of teriparatide in a patient with diffuse idiopathic skeletal hyperostosis.
  372. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.
  373. Commentary: Intermittent teriparatide enhancement of bone graft healing in a rat model of spinal glucocorticoid-induced osteoporosis.
  374. Analysis of daily teriparatide treatment for osteoporosis in men.
  375. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
  376. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
  377. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
  378. Use of pertuzumab and docetaxel desensitization in oncological patient; apropos of a case.
  379. Pertuzumab and solid tumors: perspectives.
  380. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
  381. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
  382. Role of interleukin-1 inhibitors in the management of gout.
  383. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.
  384. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.
  385. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
  386. Evaluation of Medicines for Human Use-Denosumab.
  387. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.
  388. A 45-fold liraglutide overdose did not cause hypoglycaemia.
  389. CorrelationBetween Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy.
  390. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
  391. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
  392. Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
  393. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.
  394. Liraglutide: a new treatment for type 2 diabetes.
  395. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
  396. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
  397. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
  398. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
  399. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
  400. Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: Week-112 efficacy and safety results of the open-label long-term extension of the GO-FURTHER trial.
  401. Golimumab, the newest TNF blocker, comes of age.
  402. Subacute cutaneous lupus erythematosus induced by golimumab.
  403. Arterial stiffness in kidney transplantation: a single center case-control study comparing belatacept versus calcineurin inhibitor immunosuppressive based regimen.
  405. Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: a proof-of-concept study.
  406. Transplantation: induction of chimerism and immune tolerance using belatacept.
  407. Belatacept: from rational design to clinical application.
  408. Belatacept: in adult kidney transplant recipients.
  409. Structural and functional consequences of buserelin-induced enteric neuropathy in rat.
  410. Induction of ovulation with buserelin in jennies: in search of the minimum effective dose.
  411. A stability indicating capillary electrophoresis method for analysis of buserelin.
  412. Ganglioneuritis is common in rats with enteric neuropathy due to buserelin treatment.
  413. Dry heat forced degradation of buserelin peptide: kinetics and degradant profiling.
  414. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
  415. Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment.
  416. Direct site-specific glycoform identification and quantitative comparison of glycoprotein therapeutics: imiglucerase and velaglucerase alfa.
  417. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.
  418. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
  419. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
  420. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
  421. Neuroendocrinology: Tesamorelin can improve cognitive function.
  422. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.
  423. Spotlight on tesamorelin in HIV-associated lipodystrophy.
  424. Acquired and inherited lipodystrophies.
  425. Tesamorelin: A hope for ART-induced lipodystrophy.
  426. GRF analogs and fragments: correlation between receptor binding, activity and structure.
  427. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
  428. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
  429. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
  430. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
  431. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
  432. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
  433. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation.
  434. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
  435. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
  436. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
  437. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.
  438. Belimumab: a guide to its use in systemic lupus erythematosus.
  439. Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.
  440. Belimumab for the treatment of systemic lupus erythematosus.
  441. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
  442. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
  443. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
  444. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome.
  445. Single intravitreal aflibercept injection for unilateral acute nonarteritic ischemic optic neuropathy.
  446. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
  447. An update on the pharmacotherapy of neovascular age-related macular degeneration.
  448. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
  449. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
  450. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
  451. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
  452. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
  453. In brief: asparaginase Erwinia chrysanthemi (Erwinaze) for ALL.
  455. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
  456. Incomplete vitreomacular traction release using intravitreal ocriplasmin.
  457. Research update of ocriplasmin for symptomatic vitreomacular adhesion.
  458. Macular Hole Progression following Ocriplasmin Intravitreal Injection.
  459. Glucarpidase to combat toxic levels of methotrexate in patients.
  460. Glucarpidase for the treatment of life-threatening methotrexate overdose.
  461. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
  462. Glucarpidase Intervention for Delayed Methotrexate Clearance.
  463. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity
  464. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
  465. Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.
  466. The long road to a new short-bowel therapy: teduglutide for clinical use.
  467. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.
  468. A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.
  469. Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block.
  470. Utility of a population pharmacokinetic metaanalysis during the approval process of teduglutide for the treatment of short bowel syndrome.
  471. Teduglutide for the Treatment of Short Bowel Syndrome.
  472. Raxibacumab.
  473. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.
  474. Raxibacumab: potential role in the treatment of inhalational anthrax.
  475. Raxibacumab for anthrax.
  476. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
  477. Certolizumab pegol for the treatment of psoriatic arthritis.
  478. Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis.
  479. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
  480. Effectiveness of certolizumab pegol in chronic anterior uveitis associated to Crohn's disease and ankylosing spondylitis.
  481. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
  482. Certolizumab pegol in the treatment of Crohn's disease.
  483. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
  484. Impact of human isophane insulin on the evaluation of beta cell functions.
  485. Are long-acting insulin analogues better than isophane insulin?.
  486. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
  487. Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine.
  488. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
  489. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
  490. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
  491. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
  492. Quality of original and biosimilar epoetin products.
  493. Evaluation of Medicines for Human Use- Epoeitin Zeta.
  494. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
  495. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
  496. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
  497. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
  498. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.
  499. Topical effectiveness of kiwifruit versus fibrinolysin ointment on removal of necrotic tissue of full-thickness burns in male rats.
  500. Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers.
  501. Drug-induced interstitial pneumonia associated with inhalation of fibrinolysin-deoxyribonuclease (ElaseR).
  502. Development, characterisation and diagnostic application of monoclonal antibodies against Yersinia pestis fibrinolysin and coagulase.
  503. Comfort, ease of use and practicality of the pen injector for follitropin α for assisted reproduction: an observational post-marketing study in Egypt.
  504. A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration.
  505. A comparison between follitropin α filled by mass and follitropin a filled by bioassay in the same egg donors.
  506. The redesigned follitropin α pen injector for infertility treatment.
  507. A prospective comparison of in vitro fertilization (IVF) outcome following controlled ovarian hyperstimulation (COH) regimens using follitropin alpha exclusively or with the addition of low dose human chorionic gonadotropin (hCG) and ganirelix.
  508. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.
  509. Drug evaluation: AMG-531 for the treatment of thrombocytopenias.
  510. Romiplostim: a review of its use in immune thrombocytopenia.
  511. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
  512. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
  513. Lucinactant versus poractant-alpha in premature lambs.
  514. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome.
  515. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome.
  516. Lucinactant: in neonatal respiratory distress syndrome.
  517. Lucinactant (Discovery Laboratories).
  518. The Unfolding/Denaturation of Immunogammaglobulin of Isotype 2b and its Fab and Fc Fragments.
  519. Natalizumab for active Crohn’s disease.
  520. Structure-based design of aliskiren, a novel orally effective renin inhibitor.
  521. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.
  522. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship.
  523. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
  524. Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine.
  525. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
  526. Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review
  527. Growth hormone secretion during sleep.
  528. Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis.
  529. Drotrecogin Alfa (Activated) in Adults with Septic Shock.
  530. Severe Sepsis and Septic Shock.
  531. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.
  532. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
  533. Alefacept in the treatment of psoriatic nail disease: a proof of concept study.
  534. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
  535. www.fda.gov/ohrms/dockets/ac/01/briefing/3680b2_03.pdf.
  536. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA.
  537. Contract purchasing means a buyer’s market.
  538. http://pubchem.ncbi.nlm.nih.gov/compound/Abarelix#section=Chemical-Vendors
  539. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.
  540. Sermorelin- A better approach to management of adult-onset growth hormone insufficiency?
  541. http://www.peptidesciences.com/sermorelin.
  542. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
  543. Perioperative systemic haemostatic agents.
  544. Anatomy and Taxonomy of Protein Structure.
  545. Über die Inaktivierung des kallikreins.
  546. Early experience with trasylol in the treatment of acute pancreatitis.
  547. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials.
  548. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
  549. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
  550. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
  551. Radioimmunodetection of colorectal carcinoma.
  552. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.